Nanomedicine: Redefining Cancer Therapy
Sapu Bioscience is pioneering sub-20 nm Deciparticle™ nanomedicine — transforming drug molecules into programmable biological entities.
FROM CONCEPT TO CLINIC
Our proprietary Deciparticle™ platform enables precise delivery of water-insoluble drugs by engineering ultrasmall nanoparticles (<20 nm) that behave like molecular drugs—evading immune detection, penetrating tumors, and improving bioavailability.
With a 90% success rate across over 100 tested APIs, Deciparticle™ nanomedicine accelerates IND timelines and enables next-generation cytotoxic formulations.
A comprehensive review in the
International Journal of Molecular Sciences (IJMS) surveyed 5–15 nm nanoparticles, explaining
why this ultrasmall window benefits platforms like Deciparticle™ and programs like SAPU-003:
https://doi.org/10.3390/ijms262210842
EVOLUTION OF NANOMEDICINE
▼
2005 — ABRAXANE®
The first nanoparticle chemotherapy for solid tumors, co-invented by Dr. Vuong Trieu.
▼
2010 — CYNVILOQ™
Next-generation Abraxane developed via IgDraSol using polymeric micelles instead of albumin.
▼
2025 — SAPU-003
Fourth-generation Deciparticle™ everolimus delivering 100% bioavailability and converting cytostatic to cytotoxic efficacy through dual mTORC inhibition.
SAPU-003: Intravenous Everolimus Deciparticle™
SAPU-003 transforms everolimus into an intravenous Deciparticle™ formulation with 100% bioavailability, deeper tumor penetration, and significantly reduced toxicity.
- Dual mTORC1 + mTORC2 inhibition
- Weekly IV dosing enables immune recovery
- Reduced mucositis, pneumonitis, and cytopenia
- Synergistic with metformin + statins
- View Clinical Rationale →
Manufacturing Excellence
The Sapu San Diego GMP Facility is the first permitted Deciparticle™ manufacturing site for lyophilized injectable antineoplastic products.
Collaborative Path to Phase I
- Sapu Bioscience — GMP Manufacturing
- Medicilon Group — IND Enabling Studies
- iNGENū CRO — CRO Partner
- SOCRU — Clinical Partner